Search
forLearn
5 / 801 resultslearn PTT-6®
learn Beta glucan
learn HT-B
learn Pyrithione Zinc
Research
5 / 61 results
research 568 Evaluating results of an interferon-γ release assay in patients with autoimmune skin disease on hydroxychloroquine
Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.
research 572 Defining chronic wound types in recessive dystrophic epidermolysis bullosa patients for clinical outcome assessment
The conclusion is that differentiating wound types in RDEB patients is important for clinical trials and understanding the disease.
research 569 The patient perspective on psoriasis disease remission
Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.
research 571 Role of observation for excisionally biopsied moderately dysplastic nevi with positive histologic margins and risk of development of future melanoma
Watching, not removing, skin growths with moderate atypia and positive edges is okay; patients may get melanoma elsewhere, especially if they've had it before.
research 573 A review of the use of platelet rich plasma for the treatment of androgenic alopecia
Platelet Rich Plasma can potentially help in restoring hair loss, but more research with larger groups is needed to confirm its effectiveness and standardize its use.
Community Join
5 / 1000+ resultscommunity Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Will kintor show pyrilutamide phase 3 trials result this q
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
community Chances of GT20029 hitting the black market?
The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.
community Estimate of GT20029 on the grey market?
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
community Janoshik tests of Actifolic RU-58841 powder and GhK-Cu peptide
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.